May 06, 2026 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Apr 19, 2026 6:00pm EDT KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Apr 06, 2026 7:00am EDT Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Mar 17, 2026 4:30pm EDT Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Feb 25, 2026 7:00am EST Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Feb 18, 2026 7:00am EST Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2026
Jan 09, 2026 7:00am EST Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Nov 07, 2025 8:00am EST Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Nov 06, 2025 7:00am EST Immunocore reports third quarter financial results and provides a business update
Aug 07, 2025 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Jul 31, 2025 2:00am EDT Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
May 07, 2025 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Mar 10, 2025 3:00pm EDT Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Feb 26, 2025 7:00am EST Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Feb 19, 2025 7:00am EST Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Jan 10, 2025 7:00am EST Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Jan 02, 2025 7:00am EST Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Dec 23, 2024 7:00am EST Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Dec 17, 2024 7:00am EST Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Dec 11, 2024 7:00am EST EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Dec 03, 2024 1:00am EST Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Jun 18, 2024 7:00am EDT Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024